Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Our lead product candidate, VO659, is currently in Phase 1/2a clinical development for the treatment of spinocerebellar ataxia types 3 and 1 and Huntington’s disease and is the only ASO in the clinic that targets the underlying CAG repeat expansions that cause all nine known polyglutamine diseases. Vico’s research platform designs fit-for-purpose ASOs by applying precision chemistry with mechanisms of action ideally suited to target genetic neurological diseases. For more information, visit www.vicotx.com.
 

Recent Milestones: Announced €54M Series B in January 2024
 

Upcoming Milestones: Interim clinical data from ongoing Phase 1/2a study in genetic neurodegenerative diseases in 2H 2024
 

Products: Developing VO659, lead candidate in clinic for spinocerebellar ataxia types 1 & 3 and Huntington’s disease
 

Investors: EQT, Kurma, Ackerman’s & van Haaren, Droia, Polaris, Pureos.
 

Full Company address & contact details: J.H. Oortweg 21, 2333 CH Leiden, The Netherlands